Barlow Wealth Partners Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Barlow Wealth Partners Inc. grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 1,867.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,365 shares of the company's stock after purchasing an additional 20,279 shares during the period. Eli Lilly and Company makes up about 2.5% of Barlow Wealth Partners Inc.'s portfolio, making the stock its 16th biggest position. Barlow Wealth Partners Inc.'s holdings in Eli Lilly and Company were worth $18,898,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock valued at $57,320,226,000 after buying an additional 475,530 shares during the period. Geode Capital Management LLC boosted its stake in Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after buying an additional 291,875 shares during the period. GAMMA Investing LLC increased its position in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Wellington Management Group LLP increased its position in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after acquiring an additional 2,012,129 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $8,407,908,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.0%

NYSE LLY traded up $0.32 during trading on Friday, reaching $779.60. 1,450,772 shares of the company's stock traded hands, compared to its average volume of 3,664,838. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. The company's 50 day simple moving average is $773.61 and its two-hundred day simple moving average is $799.72.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.58 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.